"For the fourth quarter 2024, SWK's core Finance Receivables segment reported an 11.6% increase in revenue to $10.3 million ...

Q4 2024 Earnings Call Transcript March 20, 2025 Mogo Inc. beats earnings expectations. Reported EPS is $-0.01, expectations ...

Fulgent Genetics has a low Price/Book ratio and promising drug candidates. Key trial results are expected in May 2025. Read ...

Conference Call Scheduled for Thursday, March 20, 2025, at 09:00 a.m. CSTCorporate HighlightsFourth quarter 2024 GAAP net income was $5.9 million, compared with GAAP net income of $2.8 million for the ...

Micron HBM revenue crosses $1 billion milestone in fiscal Q2 Strong execution and robust AI demand drives record data center DRAM revenueBOISE, ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...

MacroGenics (NASDAQ: MGNX) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

These firms may be years away from marketable ... good financial health. He also diversifies across 60-80 firms to reduce company-specific risk. The portfolio can hold up to 15% of assets in ...

MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ®, today announced its financial results for the fourth quarter and ...